Pharmaceutical care program for type 2 diabetes patients in Brazil : a randomised controlled trial.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorMourão, Aline de Oliveira Magalhães-
Autor(es): dc.creatorFerreira, Wandiclécia Rodrigues-
Autor(es): dc.creatorMartins, Maria Auxiliadora Parreiras-
Autor(es): dc.creatorReis, Adriano Max Moreira-
Autor(es): dc.creatorCarrilo, Maria Ruth Gaede Gonçalves-
Autor(es): dc.creatorGuimarães, Andrea Grabe-
Autor(es): dc.creatorEv, Lisiane da Silveira-
Data de aceite: dc.date.accessioned2025-08-21T15:51:18Z-
Data de disponibilização: dc.date.available2025-08-21T15:51:18Z-
Data de envio: dc.date.issued2017-02-09-
Data de envio: dc.date.issued2017-02-09-
Data de envio: dc.date.issued2012-
Fonte completa do material: dc.identifierhttp://www.repositorio.ufop.br/handle/123456789/7238-
Fonte completa do material: dc.identifierhttp://link.springer.com/article/10.1007/s11096-012-9710-7-
Fonte completa do material: dc.identifierhttps://doi.org/10.1007/s11096-012-9710-7-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1025850-
Descrição: dc.descriptionBackground Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients. Objective To evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes. Setting Six primary care units of the Brazilian public health system, Ouro Preto, Brazil. Method An open, randomised, controlled clinical trialwas conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels C7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C. Results A total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (-0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors. Conclusions This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsrestrito-
Palavras-chave: dc.subjectDiabetes mellitus-
Palavras-chave: dc.subjectPharmacists-
Título: dc.titlePharmaceutical care program for type 2 diabetes patients in Brazil : a randomised controlled trial.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.